Shares of Alvotech (ALVO) rallied approximately 8% during Wednesday’s trading session after Barclays analyst Glen Santangelo upgraded the biosimilar developer from Underweight to Overweight, while simultaneously doubling his price objective from $4 to $8. The surge carried the stock to roughly $5.42, although it continues to trade well below its 52-week peak of $9.25.

According to Dow Jones Market Data, the advance ranked among the most significant daily gains for the company, establishing its strongest single-session performance since the prior December. In analyst rating conventions, an Overweight designation generally signals an expectation that a stock will outperform its sector benchmark.

The rating change followed a critical regulatory milestone. In July, the U.S. Food and Drug Administration (FDA) concluded its evaluation of Alvotech’s production facility in Reykjavik, Iceland, assigning it a “Voluntary Action Indicated” designation — the agency’s most positive inspection classification.

The Icelandic manufacturing site had long been a persistent concern within the investment community. Previous FDA examinations had identified shortcomings related to production standards and facility compliance, creating obstacles for product clearances. Importantly, the products themselves passed scrutiny; only the manufacturing location required remediation.

With the facility concerns resolved, Alvotech filed revised biologics license applications in June for three biosimilar candidates. The FDA has established December 4, 2026, as the target date for rendering decisions on all three submissions.

Biosimilar Candidates Awaiting Approval

The trio of products seeking regulatory clearance targets therapeutic areas including chronic inflammatory diseases, eye care, and skeletal health. Biosimilars are biological medicines designed to be highly similar to an already-approved reference product, with no clinically meaningful differences, and they must clear FDA review before reaching the U.S. market.

AVT05 serves as a biosimilar candidate to Simponi, a Johnson & Johnson therapy designed to alleviate joint discomfort. AVT06 represents Alvotech’s biosimilar version of Eylea, jointly developed by Regeneron and Bayer to address retinal conditions and preserve vision. AVT03 is modeled on Prolia and Xgeva, both Amgen products focused on bone protection.

Additionally, the FDA has accepted a BLA submission for AVT16, a biosimilar to Entyvio, with an anticipated determination in the first quarter of 2027.

Renewed Production and Revenue Outlook

Santangelo highlighted that production operations at full capacity recommenced during the second quarter of 2026. Company leadership, meanwhile, reiterated its revenue projection of $650 million to $700 million for the current fiscal year.

Beyond its Icelandic operations, Alvotech has been pursuing additional manufacturing capabilities. The company established a collaborative arrangement with Fujifilm Biotechnologies in the United States, with enhanced production capacity anticipated to become operational in 2027.

Santangelo characterized the stock as a compelling investment opportunity, pointing to regulatory advancements and the defined timeline for potential approvals before the current year concludes.

Broader equity markets demonstrated positive momentum on Wednesday, with the S&P 500 advancing 0.2% and the Nasdaq climbing 0.4%, although Alvotech’s performance significantly exceeded these benchmark gains. The stock continues to trade substantially under its 52-week high of $9.25, with three critical FDA determinations scheduled for December 4, 2026.

This article originally appeared on Blockonomi.